| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Proto-Oncogene Proteins c-pim-1 | 35 | 2020 | 87 | 8.700 |
Why?
|
| Protein Kinase Inhibitors | 19 | 2020 | 331 | 3.450 |
Why?
|
| Proto-Oncogene Proteins | 31 | 2018 | 411 | 2.970 |
Why?
|
| Prostatic Neoplasms | 20 | 2021 | 778 | 2.690 |
Why?
|
| Apoptosis | 29 | 2019 | 1641 | 2.370 |
Why?
|
| Antineoplastic Agents | 26 | 2017 | 1070 | 2.160 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2021 | 22 | 2.040 |
Why?
|
| Biphenyl Compounds | 7 | 2018 | 184 | 1.920 |
Why?
|
| Sulfonamides | 6 | 2022 | 141 | 1.760 |
Why?
|
| Cell Line, Tumor | 28 | 2021 | 1851 | 1.630 |
Why?
|
| Phosphorylation | 45 | 2021 | 1200 | 1.610 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 12 | 2021 | 468 | 1.550 |
Why?
|
| Cell Proliferation | 18 | 2021 | 1174 | 1.520 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 9 | 2011 | 174 | 1.500 |
Why?
|
| Neoplasms | 16 | 2019 | 1667 | 1.420 |
Why?
|
| Gene Expression Regulation, Neoplastic | 10 | 2021 | 756 | 1.380 |
Why?
|
| Signal Transduction | 25 | 2020 | 2689 | 1.380 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2021 | 332 | 1.320 |
Why?
|
| Tetradecanoylphorbol Acetate | 20 | 2000 | 138 | 1.310 |
Why?
|
| Boronic Acids | 7 | 2011 | 40 | 1.310 |
Why?
|
| Lactones | 16 | 1999 | 64 | 1.300 |
Why?
|
| Pyrazines | 7 | 2011 | 46 | 1.300 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2021 | 151 | 1.290 |
Why?
|
| Mice | 60 | 2023 | 8474 | 1.280 |
Why?
|
| Transcription Factors | 16 | 2023 | 753 | 1.270 |
Why?
|
| Phosphoprotein Phosphatases | 11 | 2007 | 67 | 1.260 |
Why?
|
| Proto-Oncogene Proteins c-akt | 6 | 2019 | 331 | 1.260 |
Why?
|
| Proto-Oncogene Proteins c-jun | 17 | 2000 | 71 | 1.230 |
Why?
|
| DNA-Binding Proteins | 14 | 2023 | 700 | 1.170 |
Why?
|
| Animals | 78 | 2023 | 20881 | 1.150 |
Why?
|
| Nitrophenols | 3 | 2011 | 14 | 1.090 |
Why?
|
| Transcription, Genetic | 14 | 2021 | 562 | 1.070 |
Why?
|
| Protein-Tyrosine Kinases | 13 | 2001 | 195 | 1.050 |
Why?
|
| Humans | 127 | 2023 | 68618 | 1.010 |
Why?
|
| Protein Kinases | 9 | 2009 | 122 | 1.010 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 4 | 2008 | 19 | 1.000 |
Why?
|
| Reactive Oxygen Species | 3 | 2018 | 499 | 0.990 |
Why?
|
| Tumor Necrosis Factor-alpha | 8 | 2005 | 626 | 0.990 |
Why?
|
| Tumor Cells, Cultured | 29 | 2019 | 852 | 0.970 |
Why?
|
| Cell Cycle | 14 | 2015 | 312 | 0.960 |
Why?
|
| Thiazolidines | 4 | 2018 | 23 | 0.950 |
Why?
|
| RNA, Long Noncoding | 2 | 2021 | 54 | 0.920 |
Why?
|
| Fibroblasts | 7 | 2014 | 902 | 0.910 |
Why?
|
| Cell Survival | 13 | 2020 | 901 | 0.900 |
Why?
|
| Cell Division | 15 | 2009 | 541 | 0.870 |
Why?
|
| Membrane Glycoproteins | 6 | 2005 | 370 | 0.870 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 6 | 2001 | 17 | 0.860 |
Why?
|
| Cell Cycle Proteins | 8 | 2010 | 230 | 0.850 |
Why?
|
| Pyrimidines | 3 | 2022 | 178 | 0.820 |
Why?
|
| Cell Plasticity | 1 | 2021 | 2 | 0.810 |
Why?
|
| Hematopoietic Stem Cells | 11 | 2014 | 268 | 0.810 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2021 | 13 | 0.800 |
Why?
|
| Indazoles | 2 | 2022 | 12 | 0.800 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2020 | 28 | 0.800 |
Why?
|
| Hemangiosarcoma | 2 | 2022 | 23 | 0.790 |
Why?
|
| Perivascular Epithelioid Cell Neoplasms | 1 | 2021 | 1 | 0.790 |
Why?
|
| Trans-Activators | 6 | 2010 | 237 | 0.770 |
Why?
|
| Deoxycytidine | 2 | 2020 | 83 | 0.740 |
Why?
|
| Thiazolidinediones | 3 | 2009 | 77 | 0.740 |
Why?
|
| Cellular Senescence | 4 | 2014 | 112 | 0.740 |
Why?
|
| Transfection | 21 | 2015 | 782 | 0.730 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2014 | 78 | 0.730 |
Why?
|
| RNA, Messenger | 17 | 2021 | 1664 | 0.730 |
Why?
|
| Cell Line | 33 | 2010 | 1752 | 0.730 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2018 | 223 | 0.720 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2018 | 87 | 0.710 |
Why?
|
| Mitogen-Activated Protein Kinases | 9 | 2001 | 250 | 0.700 |
Why?
|
| Protein Kinase C | 12 | 1996 | 270 | 0.690 |
Why?
|
| Benzylidene Compounds | 2 | 2009 | 16 | 0.690 |
Why?
|
| Xenograft Model Antitumor Assays | 8 | 2020 | 304 | 0.680 |
Why?
|
| G-Quadruplexes | 1 | 2019 | 5 | 0.670 |
Why?
|
| Cell Differentiation | 18 | 2018 | 1034 | 0.660 |
Why?
|
| Protein Tyrosine Phosphatases | 8 | 2001 | 56 | 0.660 |
Why?
|
| Small Molecule Libraries | 1 | 2019 | 53 | 0.640 |
Why?
|
| Hypoxia | 2 | 2017 | 169 | 0.640 |
Why?
|
| Genes, ras | 3 | 2005 | 46 | 0.640 |
Why?
|
| Telomerase | 1 | 2019 | 85 | 0.640 |
Why?
|
| NF-E2-Related Factor 2 | 2 | 2018 | 110 | 0.640 |
Why?
|
| Promoter Regions, Genetic | 7 | 2021 | 615 | 0.600 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 8 | 1998 | 101 | 0.600 |
Why?
|
| Benzene Derivatives | 1 | 2017 | 12 | 0.590 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 8 | 1998 | 107 | 0.590 |
Why?
|
| Protease Inhibitors | 3 | 2008 | 76 | 0.590 |
Why?
|
| Biomarkers, Tumor | 3 | 2021 | 508 | 0.580 |
Why?
|
| Nose Neoplasms | 1 | 2017 | 25 | 0.580 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 5 | 2012 | 15 | 0.580 |
Why?
|
| Male | 41 | 2021 | 37321 | 0.570 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 66 | 0.560 |
Why?
|
| Leukemia | 7 | 2009 | 117 | 0.560 |
Why?
|
| Proto-Oncogene Proteins c-myc | 11 | 2020 | 90 | 0.550 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2016 | 18 | 0.540 |
Why?
|
| Leukemia, T-Cell | 1 | 2016 | 21 | 0.540 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 5 | 2008 | 65 | 0.540 |
Why?
|
| Leukemia, Experimental | 1 | 2016 | 14 | 0.540 |
Why?
|
| Eukaryotic Initiation Factors | 2 | 2014 | 11 | 0.540 |
Why?
|
| Hematopoiesis | 8 | 2013 | 108 | 0.540 |
Why?
|
| Milk Proteins | 4 | 2001 | 22 | 0.530 |
Why?
|
| Mice, Knockout | 12 | 2023 | 1692 | 0.530 |
Why?
|
| Cysteine Proteinase Inhibitors | 2 | 2011 | 73 | 0.530 |
Why?
|
| Cyclins | 6 | 2006 | 50 | 0.520 |
Why?
|
| Blotting, Western | 13 | 2010 | 954 | 0.520 |
Why?
|
| Molecular Sequence Data | 21 | 2003 | 1447 | 0.520 |
Why?
|
| Environmental Exposure | 1 | 2017 | 269 | 0.500 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2010 | 231 | 0.490 |
Why?
|
| Cyclin-Dependent Kinases | 5 | 2006 | 60 | 0.490 |
Why?
|
| Mice, SCID | 4 | 2019 | 238 | 0.480 |
Why?
|
| Prostate | 2 | 2014 | 116 | 0.470 |
Why?
|
| Growth Substances | 7 | 1999 | 77 | 0.470 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2014 | 33 | 0.470 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2011 | 446 | 0.460 |
Why?
|
| Phorbol Esters | 6 | 2004 | 37 | 0.460 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2014 | 63 | 0.460 |
Why?
|
| Pain | 1 | 2017 | 472 | 0.450 |
Why?
|
| Recombinant Fusion Proteins | 15 | 1998 | 376 | 0.450 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2013 | 100 | 0.420 |
Why?
|
| HeLa Cells | 6 | 2014 | 237 | 0.420 |
Why?
|
| Cells, Cultured | 12 | 2014 | 2673 | 0.410 |
Why?
|
| Gene Expression Regulation | 10 | 2017 | 1293 | 0.410 |
Why?
|
| RNA, Small Interfering | 7 | 2018 | 434 | 0.400 |
Why?
|
| Phosphoproteins | 4 | 2009 | 202 | 0.400 |
Why?
|
| Gene Expression Regulation, Enzymologic | 3 | 2010 | 282 | 0.390 |
Why?
|
| Bortezomib | 7 | 2011 | 45 | 0.390 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2011 | 32 | 0.390 |
Why?
|
| S-Phase Kinase-Associated Proteins | 2 | 2010 | 9 | 0.380 |
Why?
|
| Bryostatins | 16 | 1999 | 32 | 0.380 |
Why?
|
| Macrolides | 16 | 1999 | 48 | 0.370 |
Why?
|
| Proteasome Inhibitors | 2 | 2008 | 29 | 0.370 |
Why?
|
| Immediate-Early Proteins | 4 | 1998 | 63 | 0.370 |
Why?
|
| Cell Nucleus | 4 | 2021 | 305 | 0.370 |
Why?
|
| Androgen Antagonists | 4 | 2021 | 45 | 0.370 |
Why?
|
| Mice, Nude | 7 | 2015 | 294 | 0.360 |
Why?
|
| Protein Binding | 6 | 2016 | 1027 | 0.360 |
Why?
|
| Protein Processing, Post-Translational | 3 | 2006 | 284 | 0.350 |
Why?
|
| Neoplasms, Experimental | 4 | 2018 | 118 | 0.350 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 2004 | 235 | 0.340 |
Why?
|
| K562 Cells | 5 | 2010 | 44 | 0.330 |
Why?
|
| Mutation | 9 | 2021 | 1213 | 0.330 |
Why?
|
| Structure-Activity Relationship | 7 | 2019 | 420 | 0.330 |
Why?
|
| Ultraviolet Rays | 2 | 2001 | 130 | 0.330 |
Why?
|
| Flow Cytometry | 7 | 2010 | 489 | 0.330 |
Why?
|
| Disease Models, Animal | 5 | 2021 | 2550 | 0.320 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2021 | 194 | 0.320 |
Why?
|
| Sarcoma | 4 | 2013 | 70 | 0.320 |
Why?
|
| T-Lymphocytes | 3 | 2018 | 597 | 0.320 |
Why?
|
| TOR Serine-Threonine Kinases | 5 | 2020 | 118 | 0.320 |
Why?
|
| Proteins | 2 | 2010 | 474 | 0.310 |
Why?
|
| 3' Untranslated Regions | 1 | 2008 | 56 | 0.310 |
Why?
|
| Polycomb Repressive Complex 2 | 2 | 2021 | 13 | 0.310 |
Why?
|
| Drug Synergism | 3 | 2018 | 260 | 0.310 |
Why?
|
| Carrier Proteins | 4 | 2005 | 597 | 0.310 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2008 | 58 | 0.310 |
Why?
|
| Receptors, Androgen | 2 | 2021 | 34 | 0.300 |
Why?
|
| Oligopeptides | 3 | 2000 | 152 | 0.300 |
Why?
|
| Base Sequence | 13 | 1997 | 1015 | 0.300 |
Why?
|
| Enzyme Activation | 11 | 2004 | 791 | 0.300 |
Why?
|
| Protein Structure, Tertiary | 5 | 2004 | 322 | 0.300 |
Why?
|
| Leukemia, Myeloid, Acute | 6 | 2014 | 116 | 0.300 |
Why?
|
| Paclitaxel | 2 | 2007 | 140 | 0.300 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 6 | 2010 | 97 | 0.300 |
Why?
|
| Immunotherapy, Adoptive | 3 | 2018 | 132 | 0.290 |
Why?
|
| Amino Acid Sequence | 10 | 2003 | 1083 | 0.290 |
Why?
|
| Carboplatin | 1 | 2007 | 59 | 0.290 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2008 | 110 | 0.290 |
Why?
|
| Enhancer Elements, Genetic | 5 | 1995 | 63 | 0.290 |
Why?
|
| Nitriles | 3 | 2021 | 68 | 0.290 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 369 | 0.290 |
Why?
|
| Neoplastic Stem Cells | 2 | 2021 | 84 | 0.290 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2019 | 1745 | 0.280 |
Why?
|
| Molecular Structure | 4 | 2019 | 397 | 0.280 |
Why?
|
| CDC2-CDC28 Kinases | 2 | 1997 | 17 | 0.280 |
Why?
|
| Kidney Neoplasms | 1 | 2008 | 206 | 0.280 |
Why?
|
| Ethers, Cyclic | 4 | 1996 | 13 | 0.280 |
Why?
|
| G2 Phase | 1 | 2006 | 26 | 0.280 |
Why?
|
| Antigens, CD | 4 | 2014 | 230 | 0.280 |
Why?
|
| Gene Expression Profiling | 2 | 2020 | 498 | 0.270 |
Why?
|
| Up-Regulation | 4 | 2020 | 682 | 0.270 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2009 | 214 | 0.270 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 2 | 2019 | 32 | 0.260 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2010 | 710 | 0.260 |
Why?
|
| Nuclear Matrix | 1 | 2005 | 5 | 0.260 |
Why?
|
| Enzyme Inhibitors | 3 | 1998 | 659 | 0.250 |
Why?
|
| Genes, myc | 1 | 2005 | 26 | 0.250 |
Why?
|
| SOXB1 Transcription Factors | 2 | 2021 | 20 | 0.250 |
Why?
|
| Immunoprecipitation | 4 | 2005 | 132 | 0.250 |
Why?
|
| Mutagenesis, Site-Directed | 7 | 2008 | 204 | 0.250 |
Why?
|
| Ubiquitination | 2 | 2018 | 85 | 0.240 |
Why?
|
| Organoids | 2 | 2021 | 42 | 0.240 |
Why?
|
| Piperazines | 3 | 2011 | 206 | 0.240 |
Why?
|
| Binding Sites | 8 | 2004 | 631 | 0.240 |
Why?
|
| COS Cells | 6 | 2010 | 155 | 0.240 |
Why?
|
| Interleukin-3 | 6 | 2014 | 63 | 0.240 |
Why?
|
| Apoptosis Regulatory Proteins | 4 | 2005 | 100 | 0.240 |
Why?
|
| Mitochondria | 3 | 2014 | 643 | 0.230 |
Why?
|
| Janus Kinase 2 | 8 | 2001 | 40 | 0.230 |
Why?
|
| RNA Interference | 3 | 2014 | 266 | 0.230 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 3 | 1998 | 82 | 0.230 |
Why?
|
| Neoplasm Staging | 4 | 2016 | 800 | 0.230 |
Why?
|
| Neoplasm Grading | 2 | 2021 | 111 | 0.220 |
Why?
|
| Stromal Cells | 2 | 2014 | 113 | 0.220 |
Why?
|
| Interleukin-15 | 2 | 2023 | 66 | 0.220 |
Why?
|
| X-Box Binding Protein 1 | 1 | 2023 | 16 | 0.220 |
Why?
|
| Transcriptional Activation | 4 | 2010 | 226 | 0.220 |
Why?
|
| Sp1 Transcription Factor | 4 | 2000 | 21 | 0.210 |
Why?
|
| Burkitt Lymphoma | 1 | 2003 | 18 | 0.210 |
Why?
|
| Drug Administration Schedule | 6 | 2017 | 567 | 0.210 |
Why?
|
| Carcinoma, Small Cell | 4 | 1990 | 53 | 0.210 |
Why?
|
| Models, Biological | 3 | 2016 | 981 | 0.210 |
Why?
|
| Nuclear Proteins | 2 | 2003 | 271 | 0.210 |
Why?
|
| Middle Aged | 16 | 2020 | 21147 | 0.210 |
Why?
|
| Cell Growth Processes | 2 | 2013 | 40 | 0.200 |
Why?
|
| Serine | 4 | 2005 | 99 | 0.200 |
Why?
|
| Ubiquitin | 3 | 2008 | 74 | 0.200 |
Why?
|
| Ifosfamide | 1 | 2021 | 5 | 0.200 |
Why?
|
| Protein Isoforms | 2 | 2021 | 246 | 0.200 |
Why?
|
| Genes, jun | 4 | 1998 | 13 | 0.200 |
Why?
|
| Phenylthiohydantoin | 1 | 2021 | 12 | 0.200 |
Why?
|
| Melanoma, Experimental | 2 | 1996 | 95 | 0.200 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 4848 | 0.200 |
Why?
|
| Membrane Proteins | 2 | 2005 | 617 | 0.200 |
Why?
|
| Genome, Human | 1 | 2021 | 62 | 0.200 |
Why?
|
| Epithelioid Cells | 1 | 2021 | 3 | 0.200 |
Why?
|
| Female | 20 | 2021 | 38074 | 0.200 |
Why?
|
| Receptors, Somatotropin | 3 | 1996 | 4 | 0.200 |
Why?
|
| Cell Death | 2 | 2019 | 329 | 0.200 |
Why?
|
| Time Factors | 11 | 2014 | 4655 | 0.190 |
Why?
|
| Liver Neoplasms | 2 | 2017 | 334 | 0.190 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2009 | 216 | 0.190 |
Why?
|
| Cell Lineage | 1 | 2021 | 146 | 0.190 |
Why?
|
| Cathepsins | 1 | 2001 | 37 | 0.190 |
Why?
|
| Histones | 1 | 2021 | 111 | 0.190 |
Why?
|
| Antigens, Differentiation | 1 | 2001 | 49 | 0.190 |
Why?
|
| Plasmids | 6 | 2005 | 258 | 0.190 |
Why?
|
| Mice, Transgenic | 4 | 2015 | 1033 | 0.190 |
Why?
|
| Phylogeny | 1 | 2021 | 197 | 0.190 |
Why?
|
| Aged | 14 | 2020 | 14862 | 0.190 |
Why?
|
| Melanoma | 2 | 1999 | 335 | 0.190 |
Why?
|
| U937 Cells | 3 | 2009 | 61 | 0.190 |
Why?
|
| RNA Stability | 1 | 2021 | 55 | 0.180 |
Why?
|
| Benzamides | 1 | 2021 | 156 | 0.180 |
Why?
|
| Interleukin-8 | 2 | 2010 | 71 | 0.180 |
Why?
|
| Ligands | 1 | 2021 | 317 | 0.180 |
Why?
|
| DNA Methylation | 1 | 2021 | 193 | 0.180 |
Why?
|
| Viral Proteins | 2 | 1999 | 150 | 0.180 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 163 | 0.180 |
Why?
|
| MAP Kinase Signaling System | 3 | 2009 | 247 | 0.180 |
Why?
|
| Reproduction | 1 | 2020 | 48 | 0.180 |
Why?
|
| Cross-Over Studies | 1 | 2020 | 260 | 0.180 |
Why?
|
| Prognosis | 6 | 2016 | 2093 | 0.180 |
Why?
|
| Neutrophils | 3 | 1993 | 204 | 0.170 |
Why?
|
| Lung Neoplasms | 6 | 2007 | 1173 | 0.170 |
Why?
|
| Mice, Inbred NOD | 2 | 2019 | 138 | 0.170 |
Why?
|
| Glycoproteins | 2 | 2013 | 238 | 0.170 |
Why?
|
| Gene Regulatory Networks | 1 | 2020 | 94 | 0.170 |
Why?
|
| GTPase-Activating Proteins | 1 | 2019 | 21 | 0.170 |
Why?
|
| Jurkat Cells | 3 | 2009 | 59 | 0.170 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2017 | 71 | 0.170 |
Why?
|
| Luciferases | 3 | 2008 | 105 | 0.170 |
Why?
|
| Precipitin Tests | 6 | 2003 | 88 | 0.170 |
Why?
|
| Endothelial Growth Factors | 1 | 1999 | 25 | 0.160 |
Why?
|
| Lymphokines | 1 | 1999 | 49 | 0.160 |
Why?
|
| Sirolimus | 2 | 2013 | 118 | 0.160 |
Why?
|
| Peptides | 3 | 1994 | 455 | 0.160 |
Why?
|
| Bone Neoplasms | 2 | 2013 | 100 | 0.160 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 1999 | 123 | 0.160 |
Why?
|
| Cytoplasm | 6 | 2000 | 155 | 0.160 |
Why?
|
| Transplantation Immunology | 1 | 2018 | 11 | 0.160 |
Why?
|
| Leukemia, Myeloid | 2 | 1995 | 39 | 0.160 |
Why?
|
| Gene Knockdown Techniques | 2 | 2020 | 196 | 0.160 |
Why?
|
| Stem Cells | 1 | 2020 | 248 | 0.160 |
Why?
|
| Pleural Effusion | 1 | 1999 | 74 | 0.160 |
Why?
|
| Protein Stability | 1 | 2018 | 90 | 0.160 |
Why?
|
| Peptide Fragments | 3 | 2010 | 483 | 0.160 |
Why?
|
| Platelet Activation | 2 | 1999 | 24 | 0.160 |
Why?
|
| Environmental Pollutants | 1 | 2020 | 180 | 0.150 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 6 | 2001 | 140 | 0.150 |
Why?
|
| Caspases | 3 | 2004 | 194 | 0.150 |
Why?
|
| Radiation Tolerance | 1 | 1998 | 30 | 0.150 |
Why?
|
| Receptors, IgG | 2 | 1997 | 94 | 0.150 |
Why?
|
| Androgens | 1 | 1998 | 41 | 0.150 |
Why?
|
| Epithelial Cells | 3 | 2014 | 431 | 0.150 |
Why?
|
| Orchiectomy | 2 | 2013 | 25 | 0.150 |
Why?
|
| Blood Platelets | 2 | 1996 | 284 | 0.150 |
Why?
|
| Threonine | 3 | 2005 | 47 | 0.150 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 3 | 2010 | 272 | 0.150 |
Why?
|
| Dual Specificity Phosphatase 1 | 4 | 1998 | 22 | 0.150 |
Why?
|
| Facial Neoplasms | 1 | 2017 | 10 | 0.150 |
Why?
|
| Polyploidy | 2 | 2010 | 24 | 0.150 |
Why?
|
| Mice, Inbred BALB C | 4 | 2018 | 532 | 0.150 |
Why?
|
| Protein Phosphatase 1 | 4 | 1998 | 36 | 0.150 |
Why?
|
| Meta-Analysis as Topic | 1 | 2017 | 57 | 0.150 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2017 | 64 | 0.150 |
Why?
|
| Genes, Dominant | 3 | 2010 | 51 | 0.150 |
Why?
|
| Off-Label Use | 1 | 2017 | 17 | 0.150 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2015 | 135 | 0.150 |
Why?
|
| Drug Therapy, Combination | 2 | 2017 | 649 | 0.140 |
Why?
|
| Myotonic Dystrophy | 1 | 1997 | 19 | 0.140 |
Why?
|
| Cohort Studies | 2 | 2021 | 2358 | 0.140 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2017 | 59 | 0.140 |
Why?
|
| Serpins | 2 | 1999 | 205 | 0.140 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 1997 | 62 | 0.140 |
Why?
|
| Oxidation-Reduction | 1 | 2018 | 567 | 0.140 |
Why?
|
| Protein Biosynthesis | 2 | 2014 | 181 | 0.140 |
Why?
|
| bcl-2-Associated X Protein | 3 | 2003 | 111 | 0.140 |
Why?
|
| Phorbol 12,13-Dibutyrate | 1 | 1996 | 24 | 0.140 |
Why?
|
| HEK293 Cells | 2 | 2014 | 326 | 0.140 |
Why?
|
| Caspase 8 | 2 | 2008 | 40 | 0.140 |
Why?
|
| Glutathione | 1 | 2018 | 343 | 0.140 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2016 | 26 | 0.130 |
Why?
|
| Treatment Outcome | 6 | 2022 | 7029 | 0.130 |
Why?
|
| STAT5 Transcription Factor | 4 | 2001 | 18 | 0.130 |
Why?
|
| NF-kappa B | 3 | 2020 | 432 | 0.130 |
Why?
|
| Protein Subunits | 3 | 2007 | 99 | 0.130 |
Why?
|
| Immunoblotting | 3 | 2015 | 254 | 0.130 |
Why?
|
| Blotting, Northern | 6 | 2003 | 189 | 0.130 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1995 | 27 | 0.130 |
Why?
|
| Down-Regulation | 3 | 2007 | 447 | 0.130 |
Why?
|
| Adenocarcinoma | 2 | 2013 | 475 | 0.130 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2015 | 4 | 0.130 |
Why?
|
| Protein Transport | 1 | 2016 | 280 | 0.130 |
Why?
|
| Glutathione Transferase | 5 | 2003 | 166 | 0.130 |
Why?
|
| Recombinant Proteins | 5 | 2001 | 742 | 0.130 |
Why?
|
| Protein Phosphatase 2 | 3 | 2005 | 67 | 0.130 |
Why?
|
| Substrate Specificity | 4 | 2000 | 234 | 0.130 |
Why?
|
| Cycloheximide | 2 | 2003 | 50 | 0.130 |
Why?
|
| G1 Phase | 2 | 2009 | 42 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2009 | 38 | 0.120 |
Why?
|
| Proteomics | 1 | 2017 | 246 | 0.120 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2014 | 10 | 0.120 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2014 | 5 | 0.120 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 2 | 2014 | 51 | 0.120 |
Why?
|
| Phorbols | 2 | 1986 | 8 | 0.120 |
Why?
|
| Sequence Deletion | 3 | 2000 | 89 | 0.120 |
Why?
|
| Chemokine CCL5 | 1 | 2014 | 23 | 0.120 |
Why?
|
| Kinetics | 6 | 2009 | 1047 | 0.120 |
Why?
|
| Minocycline | 1 | 2015 | 61 | 0.120 |
Why?
|
| 5'-Nucleotidase | 1 | 2014 | 13 | 0.120 |
Why?
|
| Neoplasm Transplantation | 3 | 2009 | 160 | 0.120 |
Why?
|
| Aging, Premature | 1 | 2014 | 2 | 0.120 |
Why?
|
| Coculture Techniques | 1 | 2014 | 147 | 0.120 |
Why?
|
| Okadaic Acid | 4 | 1996 | 22 | 0.120 |
Why?
|
| Eukaryotic Initiation Factor-3 | 1 | 2014 | 5 | 0.120 |
Why?
|
| Carcinoma, Bronchogenic | 2 | 1984 | 18 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2022 | 219 | 0.120 |
Why?
|
| Prostate-Specific Antigen | 2 | 2013 | 138 | 0.120 |
Why?
|
| Interleukin-1beta | 1 | 2014 | 88 | 0.120 |
Why?
|
| Mitochondria, Heart | 1 | 2014 | 53 | 0.120 |
Why?
|
| Mutagenesis | 2 | 2008 | 60 | 0.120 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2008 | 111 | 0.120 |
Why?
|
| Phosphoric Monoester Hydrolases | 2 | 2005 | 22 | 0.110 |
Why?
|
| Collagen Type I | 1 | 2014 | 175 | 0.110 |
Why?
|
| Cerebral Hemorrhage | 1 | 2015 | 198 | 0.110 |
Why?
|
| Neoplasm Metastasis | 5 | 2017 | 306 | 0.110 |
Why?
|
| Carbohydrates | 1 | 2013 | 57 | 0.110 |
Why?
|
| Azides | 1 | 2013 | 56 | 0.110 |
Why?
|
| Suramin | 1 | 1993 | 9 | 0.110 |
Why?
|
| Tyrosine | 4 | 2001 | 196 | 0.110 |
Why?
|
| Cardiomegaly | 1 | 2014 | 213 | 0.110 |
Why?
|
| Hematologic Diseases | 1 | 2013 | 20 | 0.110 |
Why?
|
| Macrophages | 2 | 2001 | 647 | 0.110 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2013 | 33 | 0.110 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 244 | 0.110 |
Why?
|
| Thiazoles | 1 | 2013 | 95 | 0.110 |
Why?
|
| Heterografts | 1 | 2013 | 70 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 4 | 1998 | 150 | 0.110 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 1993 | 52 | 0.110 |
Why?
|
| Rats | 5 | 2014 | 5300 | 0.100 |
Why?
|
| Transgenes | 2 | 2010 | 92 | 0.100 |
Why?
|
| Cadherins | 2 | 2010 | 93 | 0.100 |
Why?
|
| Salmonella Infections, Animal | 1 | 1992 | 5 | 0.100 |
Why?
|
| Salmonella typhimurium | 1 | 1992 | 15 | 0.100 |
Why?
|
| Smoking Prevention | 1 | 2014 | 259 | 0.100 |
Why?
|
| Molecular Weight | 4 | 1999 | 358 | 0.100 |
Why?
|
| Health Policy | 1 | 2014 | 221 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 2 | 2013 | 511 | 0.100 |
Why?
|
| Random Allocation | 1 | 2013 | 442 | 0.100 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 1998 | 63 | 0.100 |
Why?
|
| bcl-Associated Death Protein | 2 | 2009 | 19 | 0.100 |
Why?
|
| Feedback | 2 | 2023 | 90 | 0.100 |
Why?
|
| Adult | 8 | 2020 | 21403 | 0.100 |
Why?
|
| Biomarkers | 1 | 2017 | 1593 | 0.100 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 1991 | 5 | 0.100 |
Why?
|
| Ovarian Neoplasms | 2 | 2006 | 267 | 0.100 |
Why?
|
| Cell Movement | 1 | 2014 | 630 | 0.100 |
Why?
|
| Chemokine CXCL5 | 1 | 2010 | 3 | 0.090 |
Why?
|
| Phenotype | 2 | 2013 | 947 | 0.090 |
Why?
|
| Chemokine CXCL2 | 1 | 2010 | 13 | 0.090 |
Why?
|
| Young Adult | 2 | 2020 | 5717 | 0.090 |
Why?
|
| Ionomycin | 1 | 1990 | 24 | 0.090 |
Why?
|
| Cloning, Molecular | 3 | 1997 | 357 | 0.090 |
Why?
|
| Diglycerides | 1 | 1990 | 49 | 0.090 |
Why?
|
| Myocytes, Cardiac | 1 | 2014 | 442 | 0.090 |
Why?
|
| Endoplasmic Reticulum | 1 | 2011 | 148 | 0.090 |
Why?
|
| Biomimetic Materials | 1 | 2010 | 20 | 0.090 |
Why?
|
| Apc3 Subunit, Anaphase-Promoting Complex-Cyclosome | 1 | 2010 | 5 | 0.090 |
Why?
|
| Heat-Shock Proteins | 1 | 2010 | 69 | 0.090 |
Why?
|
| S Phase | 1 | 2010 | 38 | 0.090 |
Why?
|
| Multiprotein Complexes | 1 | 2010 | 56 | 0.090 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2010 | 14 | 0.090 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 1993 | 163 | 0.090 |
Why?
|
| beta-Galactosidase | 1 | 2010 | 88 | 0.090 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 196 | 0.090 |
Why?
|
| Genomic Instability | 1 | 2010 | 41 | 0.090 |
Why?
|
| Caspase 3 | 1 | 2010 | 233 | 0.090 |
Why?
|
| Embryo, Mammalian | 1 | 2010 | 176 | 0.090 |
Why?
|
| DNA Damage | 1 | 2010 | 190 | 0.090 |
Why?
|
| Angiotensin II | 1 | 1990 | 220 | 0.090 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 3 | 2001 | 134 | 0.080 |
Why?
|
| Benzenesulfonates | 1 | 2009 | 30 | 0.080 |
Why?
|
| Colonic Neoplasms | 2 | 2017 | 299 | 0.080 |
Why?
|
| Interleukin-6 | 1 | 2010 | 330 | 0.080 |
Why?
|
| Mitosis | 2 | 2006 | 76 | 0.080 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2009 | 175 | 0.080 |
Why?
|
| Fas-Associated Death Domain Protein | 1 | 2008 | 7 | 0.080 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2008 | 18 | 0.080 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 1990 | 317 | 0.080 |
Why?
|
| Half-Life | 2 | 2000 | 96 | 0.080 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2008 | 19 | 0.080 |
Why?
|
| Tissue Distribution | 3 | 2001 | 282 | 0.080 |
Why?
|
| Response Elements | 1 | 2008 | 29 | 0.080 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2008 | 13 | 0.080 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2008 | 24 | 0.080 |
Why?
|
| Point Mutation | 2 | 1998 | 97 | 0.080 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2008 | 52 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 1026 | 0.080 |
Why?
|
| Vinblastine | 1 | 2007 | 40 | 0.080 |
Why?
|
| Topotecan | 1 | 2007 | 17 | 0.080 |
Why?
|
| Dioxoles | 1 | 2007 | 8 | 0.070 |
Why?
|
| Tetrahydroisoquinolines | 1 | 2007 | 4 | 0.070 |
Why?
|
| Oxidative Stress | 1 | 2011 | 718 | 0.070 |
Why?
|
| Rhabdomyolysis | 1 | 2007 | 16 | 0.070 |
Why?
|
| Peptidylprolyl Isomerase | 1 | 2007 | 6 | 0.070 |
Why?
|
| NIMA-Interacting Peptidylprolyl Isomerase | 1 | 2007 | 7 | 0.070 |
Why?
|
| Pyridines | 1 | 2009 | 261 | 0.070 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2007 | 57 | 0.070 |
Why?
|
| Disease-Free Survival | 3 | 2013 | 349 | 0.070 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 1988 | 146 | 0.070 |
Why?
|
| Cdc20 Proteins | 1 | 2006 | 2 | 0.070 |
Why?
|
| Nocodazole | 1 | 2006 | 11 | 0.070 |
Why?
|
| Macromolecular Substances | 3 | 1998 | 122 | 0.070 |
Why?
|
| Ubiquitin-Protein Ligase Complexes | 1 | 2006 | 1 | 0.070 |
Why?
|
| Sequence Alignment | 2 | 2000 | 165 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase 2 | 2 | 1997 | 33 | 0.070 |
Why?
|
| Antigens, CD7 | 2 | 1997 | 2 | 0.070 |
Why?
|
| Embryonic Stem Cells | 1 | 2006 | 40 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-fos | 3 | 1991 | 114 | 0.070 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 1986 | 21 | 0.070 |
Why?
|
| Receptors, Drug | 1 | 1986 | 31 | 0.070 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2006 | 89 | 0.070 |
Why?
|
| Bone Marrow Transplantation | 2 | 2018 | 149 | 0.070 |
Why?
|
| In Vitro Techniques | 3 | 1992 | 765 | 0.070 |
Why?
|
| Smoking | 1 | 2014 | 1452 | 0.070 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2005 | 17 | 0.060 |
Why?
|
| Amino Acid Substitution | 2 | 2012 | 137 | 0.060 |
Why?
|
| Growth Inhibitors | 2 | 2000 | 33 | 0.060 |
Why?
|
| Bcl-2-Like Protein 11 | 1 | 2005 | 11 | 0.060 |
Why?
|
| Butadienes | 1 | 2005 | 26 | 0.060 |
Why?
|
| Smoking Cessation | 1 | 2014 | 1034 | 0.060 |
Why?
|
| Gene Expression | 3 | 1993 | 770 | 0.060 |
Why?
|
| Nerve Tissue Proteins | 2 | 2015 | 290 | 0.060 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2005 | 69 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 1989 | 629 | 0.060 |
Why?
|
| Death Domain Receptor Signaling Adaptor Proteins | 1 | 2004 | 1 | 0.060 |
Why?
|
| Green Fluorescent Proteins | 1 | 2005 | 200 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2004 | 32 | 0.060 |
Why?
|
| Mitochondrial Proteins | 1 | 2005 | 113 | 0.060 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 1994 | 35 | 0.060 |
Why?
|
| Injections, Intravenous | 2 | 1996 | 215 | 0.060 |
Why?
|
| Aspartic Acid | 1 | 2004 | 65 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 3 | 2018 | 2791 | 0.060 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 2 | 1996 | 26 | 0.060 |
Why?
|
| Oligonucleotide Probes | 2 | 1995 | 35 | 0.060 |
Why?
|
| Chromosome Segregation | 1 | 2003 | 3 | 0.060 |
Why?
|
| RNA | 1 | 2005 | 171 | 0.060 |
Why?
|
| Phosphorus Radioisotopes | 2 | 1995 | 29 | 0.060 |
Why?
|
| Transduction, Genetic | 2 | 2001 | 81 | 0.060 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2013 | 381 | 0.060 |
Why?
|
| Genetic Vectors | 1 | 2004 | 312 | 0.060 |
Why?
|
| Caspase 9 | 1 | 2003 | 31 | 0.060 |
Why?
|
| Phosphates | 2 | 1995 | 72 | 0.060 |
Why?
|
| bcl-X Protein | 1 | 2003 | 36 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2003 | 24 | 0.050 |
Why?
|
| Thymoma | 1 | 1982 | 14 | 0.050 |
Why?
|
| Thymus Neoplasms | 1 | 1982 | 17 | 0.050 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2022 | 13 | 0.050 |
Why?
|
| Killer Cells, Natural | 1 | 2023 | 94 | 0.050 |
Why?
|
| Phospholipids | 1 | 1982 | 108 | 0.050 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 1992 | 95 | 0.050 |
Why?
|
| Isoenzymes | 2 | 2018 | 308 | 0.050 |
Why?
|
| 3T3 Cells | 2 | 2000 | 124 | 0.050 |
Why?
|
| Models, Molecular | 2 | 2017 | 546 | 0.050 |
Why?
|
| Etoposide | 1 | 2021 | 64 | 0.050 |
Why?
|
| Depsipeptides | 2 | 2000 | 21 | 0.050 |
Why?
|
| Colony-Forming Units Assay | 3 | 2013 | 78 | 0.050 |
Why?
|
| Lymph Nodes | 1 | 2003 | 258 | 0.050 |
Why?
|
| Cathepsin G | 1 | 2001 | 3 | 0.050 |
Why?
|
| Macrophage-1 Antigen | 1 | 2001 | 10 | 0.050 |
Why?
|
| Rabbits | 3 | 2000 | 509 | 0.050 |
Why?
|
| B7-2 Antigen | 1 | 2001 | 23 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2001 | 507 | 0.050 |
Why?
|
| Cost Savings | 1 | 2021 | 110 | 0.050 |
Why?
|
| Transforming Growth Factor beta | 2 | 2014 | 384 | 0.050 |
Why?
|
| Serine Endopeptidases | 1 | 2001 | 50 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase 10 | 1 | 2000 | 8 | 0.050 |
Why?
|
| Cell Membrane | 2 | 1996 | 525 | 0.050 |
Why?
|
| Amino Acid Motifs | 1 | 2000 | 77 | 0.050 |
Why?
|
| Sequence Analysis, RNA | 1 | 2020 | 34 | 0.050 |
Why?
|
| Zinc Fingers | 1 | 2000 | 17 | 0.050 |
Why?
|
| Ecotoxicology | 1 | 2020 | 4 | 0.050 |
Why?
|
| Nanog Homeobox Protein | 1 | 2020 | 6 | 0.050 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2020 | 11 | 0.050 |
Why?
|
| Proto-Oncogenes | 2 | 1990 | 37 | 0.040 |
Why?
|
| Smad3 Protein | 1 | 1999 | 33 | 0.040 |
Why?
|
| Fungal Proteins | 1 | 1999 | 37 | 0.040 |
Why?
|
| Tumor Stem Cell Assay | 2 | 1991 | 30 | 0.040 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 1999 | 56 | 0.040 |
Why?
|
| Biological Transport | 1 | 2000 | 210 | 0.040 |
Why?
|
| Homeodomain Proteins | 1 | 2020 | 157 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2001 | 455 | 0.040 |
Why?
|
| Bias | 1 | 2020 | 148 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 1999 | 147 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 1999 | 30 | 0.040 |
Why?
|
| Ascitic Fluid | 1 | 1999 | 22 | 0.040 |
Why?
|
| Survival Rate | 2 | 2013 | 1056 | 0.040 |
Why?
|
| TATA-Box Binding Protein | 1 | 1998 | 1 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2020 | 320 | 0.040 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 1998 | 8 | 0.040 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 1998 | 37 | 0.040 |
Why?
|
| Protein Conformation | 1 | 2000 | 362 | 0.040 |
Why?
|
| Culture Media, Serum-Free | 1 | 1998 | 35 | 0.040 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 1998 | 22 | 0.040 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 1999 | 40 | 0.040 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 1998 | 19 | 0.040 |
Why?
|
| Calcium | 1 | 1982 | 929 | 0.040 |
Why?
|
| Phosphotyrosine | 1 | 1998 | 41 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 2 | 2000 | 492 | 0.040 |
Why?
|
| Transplantation Tolerance | 1 | 2018 | 13 | 0.040 |
Why?
|
| Stomach Neoplasms | 1 | 1999 | 64 | 0.040 |
Why?
|
| Isoantigens | 1 | 2018 | 26 | 0.040 |
Why?
|
| Dual Specificity Phosphatase 2 | 1 | 1998 | 1 | 0.040 |
Why?
|
| Models, Immunological | 1 | 2018 | 25 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2000 | 618 | 0.040 |
Why?
|
| Adenoviridae | 1 | 1999 | 295 | 0.040 |
Why?
|
| Mollusca | 1 | 1998 | 14 | 0.040 |
Why?
|
| Microtubule-Associated Proteins | 1 | 1998 | 114 | 0.040 |
Why?
|
| Flavonoids | 1 | 1998 | 109 | 0.040 |
Why?
|
| Transplantation, Heterologous | 1 | 1998 | 122 | 0.040 |
Why?
|
| Tubulin | 1 | 1998 | 60 | 0.040 |
Why?
|
| Src Homology 2 Domain-Containing, Transforming Protein 1 | 1 | 1997 | 15 | 0.040 |
Why?
|
| Antibodies | 1 | 2018 | 241 | 0.040 |
Why?
|
| Shc Signaling Adaptor Proteins | 1 | 1997 | 26 | 0.040 |
Why?
|
| Myotonin-Protein Kinase | 1 | 1997 | 2 | 0.040 |
Why?
|
| Transcription Factor AP-1 | 1 | 1997 | 61 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 1997 | 28 | 0.040 |
Why?
|
| Proteolysis | 1 | 2017 | 97 | 0.040 |
Why?
|
| Culture Media | 2 | 1988 | 155 | 0.040 |
Why?
|
| Proteome | 1 | 2017 | 87 | 0.040 |
Why?
|
| Liver | 2 | 1993 | 1118 | 0.040 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1997 | 231 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 1997 | 144 | 0.040 |
Why?
|
| Chromosome Mapping | 1 | 1997 | 188 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2006 | 1536 | 0.030 |
Why?
|
| Transforming Growth Factors | 2 | 1986 | 12 | 0.030 |
Why?
|
| Platelet Aggregation | 1 | 1996 | 127 | 0.030 |
Why?
|
| Monocytes | 1 | 1997 | 210 | 0.030 |
Why?
|
| Mice, Inbred C3H | 1 | 1996 | 134 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 1998 | 307 | 0.030 |
Why?
|
| Tritium | 1 | 1996 | 101 | 0.030 |
Why?
|
| Interleukin-2 | 2 | 2001 | 133 | 0.030 |
Why?
|
| Epidermal Growth Factor | 2 | 1986 | 95 | 0.030 |
Why?
|
| Vaccinia virus | 1 | 1997 | 97 | 0.030 |
Why?
|
| Peptide Mapping | 2 | 2012 | 39 | 0.030 |
Why?
|
| Haplorhini | 1 | 1995 | 44 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 1 | 1996 | 89 | 0.030 |
Why?
|
| Intellectual Disability | 1 | 1997 | 114 | 0.030 |
Why?
|
| Graft vs Host Disease | 1 | 2018 | 163 | 0.030 |
Why?
|
| DNA, Complementary | 3 | 2003 | 251 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 1996 | 181 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 1995 | 119 | 0.030 |
Why?
|
| Transcription Factor AP-2 | 1 | 1995 | 9 | 0.030 |
Why?
|
| Genes, fos | 1 | 1995 | 22 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 1999 | 301 | 0.030 |
Why?
|
| S100 Calcium Binding Protein beta Subunit | 1 | 2015 | 15 | 0.030 |
Why?
|
| NADPH Oxidase 4 | 1 | 2015 | 17 | 0.030 |
Why?
|
| Leukocyte Common Antigens | 1 | 2015 | 41 | 0.030 |
Why?
|
| Transcription Factor TFIIB | 1 | 1995 | 1 | 0.030 |
Why?
|
| Transcription Factor TFIID | 1 | 1995 | 4 | 0.030 |
Why?
|
| Leucine Zippers | 1 | 1995 | 10 | 0.030 |
Why?
|
| Cross-Linking Reagents | 1 | 1995 | 80 | 0.030 |
Why?
|
| Reticulocytes | 1 | 1995 | 7 | 0.030 |
Why?
|
| Oncogenes | 1 | 1995 | 71 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 209 | 0.030 |
Why?
|
| Autoradiography | 1 | 1995 | 94 | 0.030 |
Why?
|
| Indicators and Reagents | 1 | 1995 | 63 | 0.030 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2015 | 92 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 1995 | 134 | 0.030 |
Why?
|
| Epitopes | 1 | 1995 | 146 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 1 | 2015 | 114 | 0.030 |
Why?
|
| Apyrase | 1 | 2014 | 10 | 0.030 |
Why?
|
| GPI-Linked Proteins | 1 | 2014 | 27 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2015 | 137 | 0.030 |
Why?
|
| Cytokines | 2 | 2013 | 866 | 0.030 |
Why?
|
| NADPH Oxidases | 1 | 2015 | 80 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2015 | 102 | 0.030 |
Why?
|
| Carcinogens | 1 | 1994 | 86 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 2014 | 100 | 0.030 |
Why?
|
| Cell Respiration | 1 | 2014 | 47 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2015 | 160 | 0.030 |
Why?
|
| Tosyl Compounds | 1 | 2013 | 6 | 0.030 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2013 | 5 | 0.030 |
Why?
|
| Policy Making | 1 | 2014 | 51 | 0.030 |
Why?
|
| Telomere | 1 | 2014 | 59 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 2014 | 114 | 0.030 |
Why?
|
| Gene Deletion | 1 | 1995 | 235 | 0.030 |
Why?
|
| Anilides | 1 | 2013 | 16 | 0.030 |
Why?
|
| Chickens | 1 | 1995 | 232 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2013 | 41 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 1995 | 183 | 0.030 |
Why?
|
| Taxoids | 1 | 2013 | 41 | 0.030 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2013 | 30 | 0.030 |
Why?
|
| Neoplasms, Second Primary | 1 | 2014 | 62 | 0.030 |
Why?
|
| Respiratory Burst | 1 | 1993 | 6 | 0.030 |
Why?
|
| Cyclin D2 | 1 | 1993 | 5 | 0.030 |
Why?
|
| Lymphoid Enhancer-Binding Factor 1 | 1 | 2013 | 4 | 0.030 |
Why?
|
| Dasatinib | 1 | 2013 | 17 | 0.030 |
Why?
|
| PAX5 Transcription Factor | 1 | 2013 | 9 | 0.030 |
Why?
|
| Click Chemistry | 1 | 2013 | 7 | 0.030 |
Why?
|
| Chemoradiotherapy | 1 | 2013 | 54 | 0.030 |
Why?
|
| GATA1 Transcription Factor | 1 | 2013 | 19 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 170 | 0.030 |
Why?
|
| Th17 Cells | 1 | 2014 | 116 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 1995 | 314 | 0.030 |
Why?
|
| Alkynes | 1 | 2013 | 12 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 1995 | 329 | 0.030 |
Why?
|
| Protein Engineering | 1 | 1993 | 35 | 0.030 |
Why?
|
| Receptors, CXCR4 | 1 | 2013 | 48 | 0.030 |
Why?
|
| Bromodeoxyuridine | 1 | 2013 | 37 | 0.030 |
Why?
|
| Testosterone | 1 | 2013 | 96 | 0.030 |
Why?
|
| Vincristine | 2 | 1990 | 44 | 0.030 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2014 | 127 | 0.030 |
Why?
|
| Lymphoma, B-Cell | 1 | 1993 | 40 | 0.030 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2013 | 42 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2013 | 139 | 0.030 |
Why?
|
| Glycosaminoglycans | 1 | 1993 | 88 | 0.030 |
Why?
|
| Sulfur Radioisotopes | 1 | 1992 | 11 | 0.030 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2012 | 13 | 0.030 |
Why?
|
| Methionine | 1 | 1992 | 36 | 0.030 |
Why?
|
| Chromatography, Affinity | 1 | 1992 | 73 | 0.030 |
Why?
|
| Kanamycin Resistance | 1 | 1992 | 2 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 792 | 0.030 |
Why?
|
| CDC2 Protein Kinase | 1 | 1992 | 13 | 0.030 |
Why?
|
| DNA | 1 | 1995 | 597 | 0.030 |
Why?
|
| Public Health | 1 | 2014 | 201 | 0.030 |
Why?
|
| Bone Marrow Cells | 1 | 2013 | 217 | 0.030 |
Why?
|
| Diarrhea | 1 | 1992 | 63 | 0.030 |
Why?
|
| Colony Count, Microbial | 1 | 1992 | 77 | 0.030 |
Why?
|
| Staurosporine | 1 | 1991 | 19 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2012 | 112 | 0.020 |
Why?
|
| Spleen | 1 | 1992 | 301 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2013 | 148 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 438 | 0.020 |
Why?
|
| Alkaloids | 1 | 1991 | 40 | 0.020 |
Why?
|
| Saralasin | 1 | 1990 | 5 | 0.020 |
Why?
|
| Lactoferrin | 1 | 1990 | 6 | 0.020 |
Why?
|
| Hematopoietic System | 1 | 1990 | 8 | 0.020 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1990 | 43 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2013 | 245 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 1990 | 76 | 0.020 |
Why?
|
| Phagocytosis | 1 | 1990 | 65 | 0.020 |
Why?
|
| Combined Modality Therapy | 2 | 1990 | 951 | 0.020 |
Why?
|
| Nuclear Envelope | 1 | 1989 | 8 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 1990 | 129 | 0.020 |
Why?
|
| Mitogens | 1 | 1989 | 45 | 0.020 |
Why?
|
| Lung | 1 | 1994 | 849 | 0.020 |
Why?
|
| Weight Loss | 1 | 1992 | 319 | 0.020 |
Why?
|
| Annexins | 1 | 1989 | 3 | 0.020 |
Why?
|
| Immune Sera | 1 | 1989 | 30 | 0.020 |
Why?
|
| Cross Reactions | 1 | 1989 | 57 | 0.020 |
Why?
|
| Phenylurea Compounds | 1 | 2009 | 31 | 0.020 |
Why?
|
| Niacinamide | 1 | 2009 | 31 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2021 | 7277 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 1989 | 98 | 0.020 |
Why?
|
| Combinatorial Chemistry Techniques | 1 | 2009 | 25 | 0.020 |
Why?
|
| Doxorubicin | 1 | 1990 | 231 | 0.020 |
Why?
|
| Cell-Free System | 1 | 2009 | 43 | 0.020 |
Why?
|
| Inflammation | 1 | 2015 | 1030 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 1993 | 1753 | 0.020 |
Why?
|
| Celecoxib | 1 | 2007 | 22 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1993 | 2083 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 536 | 0.020 |
Why?
|
| Cell Compartmentation | 1 | 1987 | 41 | 0.020 |
Why?
|
| Receptors, Transferrin | 1 | 1987 | 18 | 0.020 |
Why?
|
| Chronic Disease | 1 | 1992 | 1330 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2007 | 164 | 0.020 |
Why?
|
| Anaphase-Promoting Complex-Cyclosome | 1 | 2006 | 2 | 0.020 |
Why?
|
| Chromatography, Gel | 1 | 1986 | 79 | 0.020 |
Why?
|
| Chromatography, Ion Exchange | 1 | 1986 | 73 | 0.020 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 1986 | 35 | 0.020 |
Why?
|
| I-kappa B Kinase | 1 | 2006 | 40 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2007 | 190 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 1986 | 165 | 0.020 |
Why?
|
| Receptors, Immunologic | 1 | 1986 | 72 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 1986 | 248 | 0.020 |
Why?
|
| Methods | 1 | 1984 | 156 | 0.010 |
Why?
|
| ErbB Receptors | 1 | 1986 | 239 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 1984 | 125 | 0.010 |
Why?
|
| Fatigue | 1 | 2005 | 132 | 0.010 |
Why?
|
| Spindle Apparatus | 1 | 2003 | 13 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 2005 | 142 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 1990 | 3259 | 0.010 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2003 | 32 | 0.010 |
Why?
|
| NIH 3T3 Cells | 1 | 2003 | 65 | 0.010 |
Why?
|
| Adolescent | 2 | 2009 | 8912 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase Phosphatases | 1 | 2001 | 3 | 0.010 |
Why?
|
| Dual-Specificity Phosphatases | 1 | 2001 | 5 | 0.010 |
Why?
|
| Gene Library | 1 | 2001 | 68 | 0.010 |
Why?
|
| United States | 1 | 2014 | 7367 | 0.010 |
Why?
|
| Catalysis | 1 | 2001 | 123 | 0.010 |
Why?
|
| Kidney | 1 | 1986 | 945 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2001 | 161 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 1 | 1986 | 561 | 0.010 |
Why?
|
| Methyl Methanesulfonate | 1 | 2000 | 7 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2001 | 241 | 0.010 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2000 | 25 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 1984 | 371 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2001 | 368 | 0.010 |
Why?
|
| Poxviridae | 1 | 1999 | 13 | 0.010 |
Why?
|
| Fas Ligand Protein | 1 | 1999 | 64 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1999 | 334 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2001 | 1174 | 0.010 |
Why?
|
| HL-60 Cells | 1 | 1998 | 50 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 1999 | 122 | 0.010 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 1998 | 33 | 0.010 |
Why?
|
| Genetic Therapy | 1 | 1999 | 291 | 0.010 |
Why?
|
| Growth Hormone | 1 | 1996 | 51 | 0.010 |
Why?
|
| STAT3 Transcription Factor | 1 | 1996 | 86 | 0.010 |
Why?
|
| Chrysenes | 1 | 1994 | 1 | 0.010 |
Why?
|
| 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | 1 | 1994 | 1 | 0.010 |
Why?
|
| Benz(a)Anthracenes | 1 | 1994 | 2 | 0.010 |
Why?
|
| Mesocricetus | 1 | 1994 | 32 | 0.010 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 1994 | 43 | 0.010 |
Why?
|
| Cricetinae | 1 | 1994 | 262 | 0.010 |
Why?
|
| Child, Preschool | 1 | 1999 | 3187 | 0.010 |
Why?
|
| Lamin Type B | 1 | 1989 | 1 | 0.010 |
Why?
|
| Lamins | 1 | 1989 | 3 | 0.010 |
Why?
|
| Child | 1 | 1999 | 6405 | 0.000 |
Why?
|
| Colony-Stimulating Factors | 1 | 1987 | 19 | 0.000 |
Why?
|
| Luminescent Measurements | 1 | 1987 | 58 | 0.000 |
Why?
|
| Neoplasms, Nerve Tissue | 1 | 1986 | 1 | 0.000 |
Why?
|
| Bleomycin | 1 | 1986 | 67 | 0.000 |
Why?
|
| Methotrexate | 1 | 1986 | 91 | 0.000 |
Why?
|
| Mouth Neoplasms | 1 | 1986 | 206 | 0.000 |
Why?
|